Foff Erin Pennock 4
4 · MapLight Therapeutics, Inc. · Filed Jan 29, 2026
Research Summary
AI-generated summary of this filing
MapLight (MPLT) CMO Erin Pennock Withholds 44,616 Shares
What Happened Erin Pennock, Chief Medical Officer of MapLight Therapeutics (MPLT), had 44,616 shares withheld by the company to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The withholding was recorded as a disposition at $17.98 per share, with a total value of approximately $802,196. This was a tax-withholding transaction (not an open-market sale).
Key Details
- Transaction date and price: January 27, 2026 — 44,616 shares withheld @ $17.98 = ~$802,196.
- Transaction code: F (payment of exercise price or tax liability via share withholding).
- Shares owned after transaction: Not stated in the filing.
- Footnote: The withheld shares represent shares retained by the issuer to satisfy tax withholding related to RSU settlement; retained securities remain subject to a 180‑day IPO lock-up tied to the October 26, 2025 prospectus date.
- Filing timeliness: Form 4 filed January 29, 2026 for the January 27 transaction — appears to be filed within the SEC’s 2-business-day requirement.
Context This was a routine tax-withholding/cashless settlement of restricted stock units rather than an open-market sale. Such withholdings reduce the net shares delivered to the insider and do not necessarily indicate a change in the insider’s view of the company. The retained shares are also subject to the IPO lock-up noted above.
Insider Transaction Report
- Tax Payment
Voting Common Stock
[F1]2026-01-27$17.98/sh−44,616$802,196→ 390,475 total
Footnotes (1)
- [F1]Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock unit awards. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.